Skip to content

Etravirine (Intelence) approved in Europe for treatment-experienced patients

Belief in conspiracy theories means less HIV testing in South Africa

Low CD4 cell count, but not HIV treatment, increases risk of hardening of the arteries

Long-term HIV treatment cuts risk of hardening of coronary artery

Next generation first-line NNRTI, rilpivirine (TMC278) potent; lowest dose better-tolerated than efavirenz at 96 weeks

`Express care` by nurses for people starting HIV treatment decreases clinic congestion, and may improve outcomes

Heat-stable ritonavir tablet equivalent to soft gel capsule; may be approved next year

Uptake of second-line treatment `stagnant` in developing world

One in five patients at London clinic are lost to follow-up and do not attend elsewhere in the UK